AIM ImmunoTech Files Routine 8-K for Reg FD & Exhibits
Ticker: AIM · Form: 8-K · Filed: Feb 9, 2024 · CIK: 946644
| Field | Detail |
|---|---|
| Company | Aim Immunotech INC. (AIM) |
| Form Type | 8-K |
| Filed Date | Feb 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, regulation-fd, corporate-governance
TL;DR
**AIM ImmunoTech just dropped a standard 8-K, nothing wild, just keeping SEC happy.**
AI Summary
AIM ImmunoTech Inc. filed an 8-K on February 8, 2024, to disclose information under Regulation FD and to include financial statements and exhibits. This filing is a routine update, indicating the company is maintaining compliance with SEC regulations by publicly sharing information that might otherwise be selectively disclosed. For investors, this matters because it signals transparency and adherence to regulatory requirements, which can build trust and provide a baseline for evaluating the company's operational status.
Why It Matters
This filing ensures all investors have equal access to potentially material information, promoting fairness and transparency in the market.
Risk Assessment
Risk Level: low — This is a routine compliance filing and does not indicate any specific new risks or opportunities for the company.
Analyst Insight
A smart investor would note this as a standard compliance filing, indicating no immediate material news, and would continue to monitor for more substantive disclosures like clinical trial results or financial reports.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — the registrant filing the 8-K
- February 8, 2024 (date) — the date of the report
- Regulation FD (other) — the disclosure item
Forward-Looking Statements
- AIM ImmunoTech Inc. will continue to file routine compliance documents as required by the SEC. (AIM ImmunoTech Inc.) — high confidence, target: 2025-02-08
FAQ
What is the purpose of AIM ImmunoTech Inc.'s 8-K filing dated February 8, 2024?
The purpose of AIM ImmunoTech Inc.'s 8-K filing dated February 8, 2024, is to satisfy disclosure requirements under Regulation FD and to furnish Financial Statements and Exhibits, as indicated in the 'ITEM INFORMATION' section of the filing.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is AIM IMMUNOTECH INC.
What is the Commission File Number for AIM ImmunoTech Inc.?
The Commission File Number for AIM ImmunoTech Inc. is 001-27072.
What is the business address and phone number of AIM ImmunoTech Inc.?
The business address of AIM ImmunoTech Inc. is 2117 SW Highway 484, Ocala, FL 34473, and its telephone number is (352) 448-7797.
Is AIM ImmunoTech Inc. classified as an emerging growth company?
No, AIM ImmunoTech Inc. is not classified as an emerging growth company, as indicated by the unchecked box next to 'Emerging growth company' in the filing.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-02-09 15:47:35
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- 0001493152-24-005649.txt ( ) — 254KB
- aim-20240208.xsd (EX-101.SCH) — 3KB
- aim-20240208_lab.xml (EX-101.LAB) — 33KB
- aim-20240208_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM IMMUNOTECH INC. February 9, 2024 By: /s/ Thomas K. Equels